Search results
Results from the WOW.Com Content Network
Pages in category "Drugs developed by AbbVie" The following 128 pages are in this category, out of 128 total. This list may not reflect recent changes. A. ABT-436;
In June, Abbvie acquired TeneoOne and its lead compound TNB-383B. The compound is a BCMA-targeting immunotherapeutic for relapsed or refractory multiple myeloma. [30] In March 2022, AbbVie acquired Syndesi Therapeutics for up to $1 billion and its portfolio of novel modulators of the synaptic vesicle protein 2A and lead compound SDI-118.
Drugs developed by AbbVie (128 P) Pages in category "AbbVie" The following 4 pages are in this category, out of 4 total. This list may not reflect recent changes. ...
AbbVie is on track to submit the New Drug Application to the U.S. Food & Drug Administration in 2025. More on drugs: Top aging expert says these 4 FDA-approved drugs hold promise for extending life.
AbbVie will also get access to Immunogen's follow-on pipeline of ADCs, including early-stage ovarian cancer candidate IMGN-151 and a mid-stage drug pivekimab sunirine for a rare type of blood cancer.
You are likely aware that AbbVie has generated an enormous chuck of its revenue in recent years from just one drug. Immunology megablockbuster Humira brought in $9.3 billion in sales in 2012 - or ...
Drug Trade name Type Main indications Company Sales (USD millions/year) ∆ vs 2014 1 Adalimumab: Humira Biologic Rheumatoid arthritis: AbbVie Inc. 14,012 1,469 2 Ledipasvir/sofosbuvir: Harvoni Small molecule Hepatitis C: Gilead Sciences: 13,864 11,737 3 Etanercept: Enbrel Biologic Rheumatoid arthritis: Amgen. Pfizer. 8,697 4,009 4 Infliximab ...
It marks the second large deal for AbbVie in the past week, coming days after it agreed to buy cancer drug developer ImmunoGen for $10.1 billion in cash, highlighting its appetite to place big ...